Please use this identifier to cite or link to this item: https://doi.org/10.3904/kjim.2021.180
DC FieldValue
dc.titleEosinophilic endotype of chronic obstructive pulmonary disease: similarities and differences from asthma
dc.contributor.authorLi, Andrew
dc.contributor.authorChan, Hiang Ping
dc.contributor.authorGan, Phyllis XL
dc.contributor.authorLiew, Mei Fong
dc.contributor.authorWong, WS Fred
dc.contributor.authorLim, Hui-Fang
dc.date.accessioned2022-07-20T09:52:50Z
dc.date.available2022-07-20T09:52:50Z
dc.date.issued2021-11-01
dc.identifier.citationLi, Andrew, Chan, Hiang Ping, Gan, Phyllis XL, Liew, Mei Fong, Wong, WS Fred, Lim, Hui-Fang (2021-11-01). Eosinophilic endotype of chronic obstructive pulmonary disease: similarities and differences from asthma. KOREAN JOURNAL OF INTERNAL MEDICINE 36 (6) : 1305-1319. ScholarBank@NUS Repository. https://doi.org/10.3904/kjim.2021.180
dc.identifier.issn1226-3303,2005-6648
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/228958
dc.description.abstractApproximately 25% to 40% of patients with chronic obstructive pulmonary disease (COPD) have the eosinophilic endotype. It is important to identify this group accurately because they are more symptomatic and are at increased risk for exacerbations and accelerated decline in forced expiratory volume in the 1st second. Importantly, this endotype is a marker of treat ment responsiveness to inhaled corticosteroid (ICS), resulting in decreased mortality risk. In this review, we highlight differences in the biology of eosinophils in COPD compared to asthma and the different definitions of the COPD eosinophilic endotype based on sputum and blood eosinophil count (BEC) with the corresponding limitations. Although BEC is useful as a biomarker for eosinophilic COPD endotype, optimal BEC cutoffs can be combined with clinical characteristics to improve its sensitivity and specificity. A targeted approach comprising airway eosinophilia and appropriate clinical and physiological features may improve identification of subgroups of patients who would benefit from biologic therapy or early use of ICS for disease modification.
dc.language.isoen
dc.publisherKOREAN ASSOC INTERNAL MEDICINE
dc.sourceElements
dc.subjectScience & Technology
dc.subjectLife Sciences & Biomedicine
dc.subjectMedicine, General & Internal
dc.subjectGeneral & Internal Medicine
dc.subjectPulmonary disease
dc.subjectchronic obstructive
dc.subjectInhaled corticosteroids
dc.subjectEosinophilia
dc.subjectPOST-HOC ANALYSIS
dc.subjectINHALED CORTICOSTEROIDS
dc.subjectDOUBLE-BLIND
dc.subjectSPUTUM EOSINOPHILIA
dc.subjectBLOOD EOSINOPHILS
dc.subjectOVERLAP SYNDROME
dc.subjectPARALLEL-GROUP
dc.subjectCLINICAL PHENOTYPES
dc.subjectAIRWAY INFLAMMATION
dc.subjectEXACERBATION RISK
dc.typeReview
dc.date.updated2022-07-17T03:35:47Z
dc.contributor.departmentDEPT OF MEDICINE
dc.contributor.departmentDEPT OF PHARMACOLOGY
dc.description.doi10.3904/kjim.2021.180
dc.description.sourcetitleKOREAN JOURNAL OF INTERNAL MEDICINE
dc.description.volume36
dc.description.issue6
dc.description.page1305-1319
dc.published.statePublished
Appears in Collections:Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Eosinophilic endotype of chronic obstructive pulmonary disease similarities and differences from asthma.pdf450.79 kBAdobe PDF

OPEN

PublishedView/Download

SCOPUSTM   
Citations

1
checked on Jul 20, 2022

Page view(s)

42
checked on Dec 1, 2022

Download(s)

2
checked on Dec 1, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.